BofA lowered the firm’s price target on BioNTech (BNTX) to $143 from $147 and keeps a Buy rating on the shares after the company reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback